| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d3d16ea8a165e9c14beba22c800cd1c6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04 |
| filingDate |
2020-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5915e142e40b82f76e6491af9b086bb7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10cc7c00b690d5ad521d76198f51a1ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_753bec85f6fef60863d780618829ad6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd11cd196259ffbfa47c5bed376b5434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c615a15fc1bac705e497d65ea5f83d9 |
| publicationDate |
2022-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3994138-A1 |
| titleOfInvention |
ESTROGEN-RELATED RECEPTOR ALPHA (ERRalpha) MODULATORS |
| abstract |
The present invention is directed to compounds according to Formula (I) and the pharmaceutically acceptable salts thereof. The compounds can be used as modulators of Estrogen-related Receptor alpha (ERRĪ±) and have utility in the treatment of ERRĪ±-mediated diseases or conditions. |
| priorityDate |
2019-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |